AU2021277517A1 - MEK-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm - Google Patents
MEK-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm Download PDFInfo
- Publication number
- AU2021277517A1 AU2021277517A1 AU2021277517A AU2021277517A AU2021277517A1 AU 2021277517 A1 AU2021277517 A1 AU 2021277517A1 AU 2021277517 A AU2021277517 A AU 2021277517A AU 2021277517 A AU2021277517 A AU 2021277517A AU 2021277517 A1 AU2021277517 A1 AU 2021277517A1
- Authority
- AU
- Australia
- Prior art keywords
- cov
- sars
- mek inhibitor
- atr
- covid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20175739.0 | 2020-05-20 | ||
| EP20175739.0A EP3912623B1 (en) | 2020-05-20 | 2020-05-20 | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| PCT/EP2021/063485 WO2021234097A1 (en) | 2020-05-20 | 2021-05-20 | Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021277517A1 true AU2021277517A1 (en) | 2022-12-08 |
Family
ID=70802645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021277517A Pending AU2021277517A1 (en) | 2020-05-20 | 2021-05-20 | MEK-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230241014A1 (https=) |
| EP (2) | EP3912623B1 (https=) |
| JP (1) | JP2023526836A (https=) |
| KR (1) | KR20230013077A (https=) |
| CN (1) | CN116635022A (https=) |
| AU (1) | AU2021277517A1 (https=) |
| BR (1) | BR112022023013A2 (https=) |
| CA (1) | CA3178137A1 (https=) |
| ES (1) | ES2995196T3 (https=) |
| MX (1) | MX2022014561A (https=) |
| WO (1) | WO2021234097A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973960B1 (en) | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| WO2023084489A1 (en) * | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| US20240165099A1 (en) * | 2022-09-30 | 2024-05-23 | 60 Degrees Pharmaceuticals Llc | Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine |
| CN116270588B (zh) * | 2022-12-26 | 2025-07-25 | 中国科学技术大学 | Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1420778B1 (en) * | 2001-03-06 | 2006-11-22 | Dorian Bevec | Use of mek inhibitors for treating virus induced hemorrhagic shock or fever |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
-
2020
- 2020-05-20 EP EP20175739.0A patent/EP3912623B1/en active Active
- 2020-05-20 ES ES20175739T patent/ES2995196T3/es active Active
-
2021
- 2021-05-20 CN CN202180059642.7A patent/CN116635022A/zh active Pending
- 2021-05-20 JP JP2022570454A patent/JP2023526836A/ja active Pending
- 2021-05-20 CA CA3178137A patent/CA3178137A1/en active Pending
- 2021-05-20 KR KR1020227044294A patent/KR20230013077A/ko active Pending
- 2021-05-20 AU AU2021277517A patent/AU2021277517A1/en active Pending
- 2021-05-20 EP EP21731684.3A patent/EP4153159A1/en active Pending
- 2021-05-20 US US17/999,185 patent/US20230241014A1/en active Pending
- 2021-05-20 MX MX2022014561A patent/MX2022014561A/es unknown
- 2021-05-20 WO PCT/EP2021/063485 patent/WO2021234097A1/en not_active Ceased
- 2021-05-20 BR BR112022023013A patent/BR112022023013A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230241014A1 (en) | 2023-08-03 |
| BR112022023013A2 (pt) | 2022-12-20 |
| ES2995196T3 (en) | 2025-02-07 |
| EP3912623A1 (en) | 2021-11-24 |
| CA3178137A1 (en) | 2021-11-25 |
| CN116635022A (zh) | 2023-08-22 |
| KR20230013077A (ko) | 2023-01-26 |
| EP4153159A1 (en) | 2023-03-29 |
| EP3912623B1 (en) | 2024-07-31 |
| JP2023526836A (ja) | 2023-06-23 |
| EP3912623C0 (en) | 2024-07-31 |
| WO2021234097A1 (en) | 2021-11-25 |
| MX2022014561A (es) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230241014A1 (en) | Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm | |
| Shemesh et al. | SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon | |
| Amirian et al. | Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses | |
| Severa et al. | Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection | |
| Cao et al. | Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence | |
| Luoni et al. | Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome | |
| Faist et al. | Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier | |
| Zhang et al. | Tick-borne encephalitis virus induces chemokine RANTES expression via activation of IRF-3 pathway | |
| Travanty et al. | Differential susceptibilities of human lung primary cells to H1N1 influenza viruses | |
| EP4146192A1 (en) | Methods and compositions for the treatment of sars-cov-2 | |
| CN116249520A (zh) | 使用WNT/β-连环蛋白通路抑制剂阻断SARS-COV-2和其他致病病毒的复制 | |
| Du et al. | Alisol B 23-acetate broadly inhibits coronavirus through blocking virus entry and suppresses proinflammatory T cells responses for the treatment of COVID-19 | |
| EP4186500A1 (en) | Mek inhibitors for the prevention and treatment of long covid syndrome | |
| US20230310421A1 (en) | Molecules for use in the treatment of viral infections | |
| EA051538B1 (ru) | Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19 | |
| CN101365474B (zh) | 用于治疗呼吸道疾病的干扰素λ疗法 | |
| Bravo-Silva et al. | Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections | |
| Kumar et al. | Mucosal implications of oral Jak3-targeted drugs in COVID patients | |
| Aldahlawi et al. | Spotlight on Immunity against COVID-19 with Emphasis on Cytokine Storm | |
| Labach | In Vitro and In Vivo Characterization of the Metallodrug BOLD-100 as an Inhibitor of SARS-CoV-2 Replication | |
| Viox | Characterizing and targeting inflammation in COVID-19 using a rhesus macaque model of SARS-CoV-2 infection | |
| Lønskov et al. | Viral infection and brain inflammation with seizures in PARK7 deficiency | |
| Alonso et al. | Virology today in Spain. Selected topics from the XVI Spanish Virology | |
| US20230381125A1 (en) | Compositions and methods for ameliorating medical conditions | |
| CN121868284A (zh) | 用于防治新型冠状病毒感染的药物组合物 |